CANTOS subanalysis: Effect of Canakinumab on New Onset Diabetes in Pre-Diabetic Patients Dr. Everett and Dr. Gibson Discuss

ACC 2018 – Wrap Up in German Dr. Silber Presents

TREAT: Ticagrelor vs. Clopidogrel After Thrombolytic Therapy in STEMI Patients Dr. Berwanger and Dr. Daaboul Discuss

ACC 2018 – Wrap Up from a Pacific Rim Perspective Dr. Daniel Scherer and Dr. Phil Aylward Discuss

ACC 2018 – Wrap Up from a Canadian Perspective Dr. John Eikelboom Presents

ACC 2018 Wrap-up in Arabic Dr. Chadi Alraies Presents

CANTOS Trial: Canakinumab Reduces MACE and Mortality Among CKD Patients Dr. Ridker and Dr. C. Michael Gibson

ACC 2018 Daily Wrap-Up – March 11, 2018 Dr. Ajay Kirtane and Dr. C. Michael Gibson Discuss

ACC 2018 Hebrew Wrap Up Dr. Doron Zahger and Dr. Basil Lewis

ACC 2018 Wrap-Up: Prof. Freek Verheugt’s Perspective Dr. Freek Verheugt Presents

ACC 2018 Japanese Wrap-Up Dr. Ogawa Presents

ACC 2018 Italian Wrap Up Dr. Gennaro Sardella Discusses

MANAGE Trial: Dabigatran in Patients With MI After Non-Cardiac Surgery Dr. PJ Devereaux and Dr. Gibson Discuss

ODYSSEY Outcomes: Alirocumab Reduces MACE, Non-fatal MI, Ischemic Stroke, and All-Cause Mortality in ACS Patients Dr. Schwartz and Dr. Gibson Discuss

VEST trial: Prevention of Early Sudden Death Post-MI Dr. Olgin and Dr. Daaboul Discuss

SWAP 4: Pharmacodynamic Effects of Switching from Ticagrelor to Clopidogrel in Patients with Coronary Artery Disease Dr. Angiolillo and Dr. Gibson Discuss

ACC 2018 Daily Wrap-Up – March 10, 2018 Dr. Kirtane and Dr. Gibson Discuss

ODYSSEY Demonstrates a Mortality Benefit in ACS Patients

Results of the much anticipated ODYSSEY Outcomes trial were presented today by Professor Phillipe Gabriel Steg, who is the chief of cardiology at Bichat-Claude Bernard Hospital, at the American College of Cardiology (ACC) Scientific Sessions in Orlando. Alirocumab, a monoclonal antibody directed against PCSK9, reduced major adverse cardiovascular events (MACE), myocardial infarction (MI), ischemic stroke and all-cause mortality in patients post-acute coronary syndrome (ACS), who were on high-intensity statin therapy. Continue reading →

Incorporating Non-Invasive Fractional Flow Reserve into Clinical Practice Dr. Jeffrey Popma and Dr. Campbell Rogers Discuss

Anticipating ODYSSEY Outcomes Dr. Christopher Cannon and Dr. C. Michael Gibson Discuss